Ozempic face and the other body changes: what rapid weight loss does to skin and hair
Ozempic face is subcutaneous fat leaving the cheeks and temples. Rapid weight loss by any route does the same thing. Neither the Wegovy label nor the Zepbound label mentions it, because no pivotal trial measured facial appearance. Nothing applied to the surface of skin puts fat back underneath it. What helps is narrower: the pace you lose at, protein, resistance training, sun protection, and a handful of clinical procedures.
- Ozempic face is fat loss. Your face stores fat in compartments under the skin. Lose 15 to 21 percent of your body weight and they shrink along with everything else. Whether the drug contributes anything beyond that is an open question that two reviews raise and neither settles.
- No topical product restores facial volume. The interventions with evidence behind them are dermal filler, biostimulatory injectables, fat transfer and surgery.
- Hair shedding is real and usually temporary. Both labels report it and both attribute it to the weight reduction rather than the molecule. The shed commonly runs three to six months, and density takes longer to come back.
- Muscle loss is the change you can act on. A 2026 systematic review of 35 randomized studies put the median muscle share of total weight lost at 28.3 percent. Resistance training and higher protein intake both have randomized evidence behind them.
What "Ozempic face" actually is
The face stores fat in discrete compartments beneath the skin: the cheeks, the temples, the area around the eyes. Weight loss draws on those compartments the way it draws on fat everywhere else, and the face has less to give than the abdomen does. The visible outcome is hollowing and a jawline that looks slacker than it did, and because hollowing is also what age does to a face, it reads as aging.
The magnitudes sit on the labels. Zepbound's prescribing information reports mean weight change at 72 weeks of 15.0 percent at 5 mg, 19.5 percent at 10 mg and 20.9 percent at 15 mg. STEP 1, the pivotal semaglutide 2.4 mg study, reported a mean 14.9 percent at 68 weeks.
A 2024 review in the Journal of Drugs in Dermatologyasks whether "Ozempic face" is a novel adverse effect or a natural consequence of rapid weight loss, and lands on the second. People who lose weight quickly by dieting, by illness or after bariatric surgery end up with the same face. A 2025 systematic review of 51 studies of the dermatologic effects of GLP-1 agonistsgives the topic a section of its own, titled "Ozempic Face: Dermatological Impact of Rapid Weight Loss." Its conclusion is that the medication "promotes systemic fat reduction rather than directly affecting facial fat cells."
Two later reviews complicate that. Ridha and colleagues in the Aesthetic Surgery Journal and Paschou and colleagues in Endocrine both argue that loss of fat volume may not be the whole mechanism. They propose effects on adipose-derived stem cells, on dermal white adipose tissue and on the fibroblasts that make collagen. Both are reviews of proposed mechanism rather than measurements in patients, and Paschou's own conclusion is that the additional mechanisms "have to be elucidated."
Neither the Wegovy prescribing information nor the Zepbound prescribing information contains a facial-volume term, a skin-laxity term or a dental term anywhere in the document. That silence is not evidence the changes do not happen. A label lists the adverse reactions the sponsor's studies counted. No pivotal study counted facial appearance, so there is nothing to list. Hair loss is on both labels.
What no topical product can do
Facial volume loss is a change in the fat layer beneath the dermis. A topical product is applied to the stratum corneum, the outermost layer of dead cells, and between the two sit the living epidermis and the full thickness of the dermis. No cosmetic ingredient crosses that distance and rebuilds a fat compartment. No serum, oil, peptide or home device has been shown to.
What the aesthetic literature reaches for instead is a list of procedures. Humphrey and Lawrence, in Facial Plastic Surgery, name dermal fillers, skin-tightening techniques and surgery for both volume restoration and excess skin. Haykal and colleagues, in the Journal of Cosmetic Dermatology, describe the same set plus biostimulatory agents and energy-based devices, and note that empirical data on timing and sequencing is thin. Ridha and colleagues add autologous fat transfer, which reintroduces the tissue that left.
Each of those needs a clinician, and each has a cost and a recovery. The two options that are not procedures are regaining weight and losing it more slowly in the first place. If a product page tells you a cream reverses facial volume loss, that is either a drug claim the product is not approved to make, or it is wrong.
What topical products can do, and how strong the evidence is
Skin quality is a different endpoint from facial volume, and some of it does respond to what you put on your face.
| Topical | What the evidence supports | Evidence grade | What it does not do |
|---|---|---|---|
| Daily broad-spectrum sunscreen | Slows measurable skin aging. Over 4.5 years in a randomized community trial of 903 adults, the daily-sunscreen group showed no detectable increase in skin aging, and 24 percent less aging than the group left to use it at their discretion | Randomized controlled trial with a hard endpoint (Hughes 2013) | Restore volume. Tighten laxity |
| Tretinoin (prescription retinoid) | Improves photoaged skin: fine wrinkling, roughness and pigmentation, with histologic change on biopsy | Double-blind vehicle-controlled trials since 1988 (Weiss 1988) | Restore volume. Tighten laxity |
| Retinol and retinyl esters (over the counter) | In one 24-week randomized study of 20 patients, a 1.1 percent precursor formulation was not significantly different from tretinoin 0.02 percent on photoaging score, and caused redness about a sixth as often | One small randomized trial, so an underpowered null rather than proven equivalence (Chien 2022) | Restore volume. Tighten laxity |
| Cosmetic peptides | Appearance of photoaged skin. A 2024 systematic review of photoaging cosmeceuticals graded the peptide evidence the strongest of the topical categories it examined, mostly at level Ib | Level Ib within a cosmetic-endpoint literature (Chan 2024). How much peptide crosses the outer layer of skin is unresolved (Zdrada-Nowak 2025) | Restore volume. Tighten laxity |
| GHK-Cu (copper tripeptide) | Studied in cell culture and animal models for collagen synthesis, tissue remodeling and wound repair (Pickart 2015) | Mechanistic and preclinical. Human cosmetic-endpoint data is limited | Restore volume. Tighten laxity. Nothing published on it supports a clinical outcome claim |
| Moisturizer and barrier repair | Hydration, comfort and the appearance of smoothness | Cosmetic | Restore volume. Tighten laxity |
Every row above is a cosmetic claim, meaning a claim about appearance. Under US law, a product that claims to change the structure or any function of the body becomes a drug and needs approval to be sold as one. The legal boundary and the biological one land in the same place.
Loose skin: what helps and when it becomes a surgical question
Skin that has been stretched for years does not always retract when the volume under it goes. The best measurements come from bariatric surgery, where the weight loss is large and the follow-up is long. In a survey of 252 gastric-bypass patients in Vienna, 96 percent reported surplus skin, frequently with skin-fold rash and itching, and 75 percent of women and 68 percent of men said they wanted body-contouring surgery.
Whether GLP-1 weight loss produces the same rate is unknown. The magnitudes overlap at the top of the tirzepatide dose range, but the pace, the population and the starting weights differ, and nobody has run the comparison. Anyone quoting you a percentage for loose skin on a GLP-1 is quoting the bariatric literature without saying so.
Losing more slowly is the most plausible lever, and it has never been tested against skin retraction in a randomized study. Age, how long the skin was stretched, sun exposure and smoking all appear in the clinical reviews as factors, and of those only sun exposure is still modifiable once the weight is off. We looked for a randomized trial of any topical product or home device for skin left loose by large weight loss and did not find one.
A 2018 systematic review and meta-analysis found that body contouring after bariatric weight loss produced statistically significant improvements in physical functioning, psychological wellbeing and social functioning. That is major surgery with a long recovery, and in the US it is frequently not covered unless the skin is causing a documented medical problem.
Hair shedding: the labeled rate and how long it lasts
Hair is the one change in this cluster that both manufacturers measured and both labels report. Each label attaches the same causal sentence to the number.
| Drug | Hair loss on drug | Hair loss on placebo | What the label says about the cause |
|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | 3.3% (4% of women, 0.9% of men) | 1% (2% of women, 0% of men) | "Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction." |
| Zepbound (tirzepatide) 5 mg | 5% | 1% | "Hair loss adverse reactions in ZEPBOUND-treated patients were associated with weight reduction." |
| Zepbound (tirzepatide) 10 mg | 4% | 1% | Same attribution to weight reduction |
| Zepbound (tirzepatide) 15 mg | 5% | 1% | Same attribution to weight reduction |
Two things about that table. The tirzepatide figures do not rise with dose, and 5, 4 and 5 percent is what the label reports rather than a transcription error. And both manufacturers, in a document the FDA approved, attribute the shedding to the weight reduction rather than to the molecule.
The pattern behind it is telogen effluvium a diffuse non-scarring shed, not patchy bald spots. A physiological stress, most often childbirth, surgery, fever or sudden weight loss, pushes an unusual share of follicles out of the growing phase at once, and the shed appears about two to three months later. The standing review in the Journal of Dermatological Science describes a high rate of remission, and also says plainly that there is no targeted treatment for it. The shedding phase commonly runs three to six months once weight stabilizes. Density takes longer to come back, because every follicle that shed has to regrow from the beginning. A 2025 dermatology review puts telogen effluvium at the center of the GLP-1 hair picture.
Two 2025 cohort studies in the Journal of the American Academy of Dermatology complicate the tidy version. Burke and colleagues found an association between GLP-1 receptor agonist use and hair loss, and Neubauer and colleagues found a higher telogen effluvium risk with tirzepatide than with other weight-loss medications. Both are retrospective database analyses rather than randomized comparisons, so they show an association without establishing how large it is.
Nutrition is the one thing here you can change yourself. Shedding after rapid weight loss is repeatedly linked in the dermatology literature to caloric and protein deficit and to iron status. The lever there is eating properly on a drug that removes your appetite, rather than buying a hair supplement.
Muscle and body composition
The most useful number on this page is not about skin. A 2026 systematic review in Annals of Internal Medicine pulled 35 randomized studies of liraglutide, semaglutide, tirzepatide and dulaglutide and looked at what the weight lost was made of. Across agents and measurement methods, the median share of total weight loss attributable to muscle-based indices was 28.3 percent, with an interquartile range of 15.9 to 39.9 percent. About two thirds of the incretin groups exceeded the review's prespecified benchmark of roughly 25 percent.
Among the comparator groups in the same review, the ones that lost weight through lifestyle change or placebo, nearly half also exceeded their benchmark. This is what weight loss does, not something the drug does uniquely. The review also reports that no study measured objective physical function, so what the muscle number means for how strong you are remains unanswered.
Two interventions have randomized evidence behind them, both from the general weight-loss literature rather than from a GLP-1 study. Resistance exercise mitigated the fall in muscle protein synthesis during a 40 percent energy deficit in a controlled study at McMaster. Higher protein intake combined with exercise additively improved body composition over four months in a randomized study of 48 women. Neither study used a GLP-1, and neither measured anything about faces or skin. Nobody has shown that protein or training prevents facial volume loss.
The maintenance dose you settle on determines how much weight you hold off, and therefore how much of all of this you live with. That decision has a price attached to it, which is covered in the maintenance dose protocols guide. The muscle and bone sections of the side effects pillar go deeper on the clinical side, and the protein calculator will give you a daily target to work from.
Teeth and dry mouth: what is actually known
"Ozempic teeth" is a search term, not a finding. No controlled study has measured dental outcomes on a GLP-1 medication, and neither prescribing information lists a dental adverse reaction or dry mouth anywhere in the document.
What both labels do list is vomiting, which runs between roughly 9 and 24 percent depending on the drug and the dose (the rates are in the side effects chart). Repeated acid exposure erodes enamel. That is established dentistry applied to a labeled side effect rather than a measured GLP-1 finding. If you are vomiting regularly on a GLP-1, raise it with both the prescriber and a dentist.
Why there is no prevalence table for facial volume loss
No pivotal study measured facial appearance as an endpoint. What exists instead is patient reporting, adverse-event database extracts and dermatology case literature. Numbers derived from those sources can be assembled into a table with week bands and dose columns, and that table would look exactly as authoritative as one built from trial data. The timeline below gives what is known about when things change, with the source for each row.
What changes and when
| Roughly when | What tends to change | What stands behind it |
|---|---|---|
| Months 0 to 3 | Titration weeks. Gastrointestinal effects dominate. Weight loss has started but facial change is rarely what people notice yet | Labeled adverse reactions and the pivotal trial curves |
| Months 3 to 6 | Shedding often appears in this window, roughly two to three months behind the fastest phase of loss. Facial change becomes visible | Telogen effluvium timing from the dermatology literature. Facial timing is observational |
| Months 6 to 12 | Most of the total weight loss has happened by around week 68 to 72. Facial volume change and any skin laxity have mostly reached their full extent. Shedding usually settles | STEP 1 and SURMOUNT-1 weight curves. Remission course from the telogen effluvium review |
| Month 12 onward | Maintenance. Facial volume does not return while the weight stays off. Skin that has not retracted by now largely will not. Muscle can still be gained or lost | Body-composition review and the aesthetic-medicine reviews. No trial has followed faces |
Treat those windows as typical rather than scheduled. Rate of loss, starting weight, age and dose all move them, and none of the rows above comes from a study designed to measure timing.
What to do next
If the change bothering you is volume, book with a board-certified dermatologist or plastic surgeon and ask what a procedure would cost and what it would not fix. Hair shedding usually runs three to six months once weight stabilizes, and density takes longer to come back. Patchy loss, scalp inflammation, or shedding that comes with fatigue and cold intolerance is a different problem and needs looking at sooner. For muscle, start resistance training and hit a protein target. Changing the pace of your weight loss is a dose conversation with your prescriber, not one to have alone.
This page is reference material and not medical advice. Nothing here replaces the clinician who prescribed your medication.
Frequently asked questions
Is Ozempic face permanent?
The fat does not come back on its own while you hold the weight loss. Dermatology and plastic-surgery reviews treat facial volume as something restored by a procedure, dermal filler, biostimulatory injectable or autologous fat transfer, or by regaining weight. Skin texture and firmness are a separate question from volume, and those do respond partly to time, to daily sun protection and to prescription retinoids.
Will a collagen supplement or a peptide serum fix it?
No. Facial volume loss is a reduction in the fat layer beneath the dermis. A topical product acts on the surface of the skin, and an oral collagen supplement is digested into amino acids that the body allocates as it chooses. Neither rebuilds a facial fat compartment. Topical peptides have reasonable evidence for the appearance of photoaged skin, which is a different endpoint, and even there how much of the peptide crosses the outer layer of skin is unresolved.
Does losing weight more slowly prevent it?
It is the most plausible lever and it has never been tested directly. No randomized trial has compared rates of weight loss against facial volume or skin retraction. The mechanism points that way and the dermatology reviews say the same thing, but nobody has measured it. Treat slower loss as reasonable rather than proven, and take any dose decision to your prescriber rather than adjusting it yourself.
Will my hair grow back?
Usually. The pattern reported on GLP-1 medication is telogen effluvium, a diffuse non-scarring shed triggered by a physiological stress such as sudden weight loss. It has a high rate of remission. The shedding phase commonly runs three to six months once weight stabilizes, and getting density back takes longer than that, because each follicle has to regrow from the beginning. Patchy loss rather than diffuse shedding, scalp inflammation, or shedding alongside fatigue and cold intolerance is a different problem and needs a clinician.
Is Ozempic face listed as a side effect on the label?
No. Neither the Wegovy prescribing information nor the Zepbound prescribing information contains any facial-volume, facial-fat or skin-laxity term. That absence is not evidence the change does not happen. A label lists the adverse reactions the sponsor's studies counted, and no pivotal study counted facial appearance. Hair loss is on both labels, at 3.3 percent on Wegovy and 4 to 5 percent on Zepbound against 1 percent on placebo.
Does everyone on a GLP-1 get facial hollowing?
Nobody has published a rate, because no controlled study has measured it. What is measurable is the weight loss that drives it: about 15 percent of body weight on semaglutide 2.4 mg at 68 weeks, and 15 to 21 percent on tirzepatide at 72 weeks depending on dose. Facial change tracks how much fat you lose and how much your face had to begin with. That is why it shows up more at the top of the dose range and in people who were already lean in the face.
Sources
Evidence checked August 17, 2026
Each clinical claim above links to the document it came from, so you can read the source instead of trusting us. GLP Chart has no medical reviewer, and does not borrow a name for one. What that means.
- Hair loss rate on semaglutide, the label's attribution of it to weight reduction, and the absence of any facial-volume or dental termCurrent FDA prescribing information for Wegovy (DailyMed)
- Hair loss rate by tirzepatide dose, mean weight change at 72 weeks, and the absence of any facial-volume or dental termCurrent FDA prescribing information for Zepbound (DailyMed)
- Mean weight loss on semaglutide 2.4 mg at 68 weeksSTEP 1: once-weekly semaglutide in adults with overweight or obesity (NEJM, 2021)
- Mean weight loss on tirzepatide at 72 weeksSURMOUNT-1: tirzepatide once weekly for the treatment of obesity (NEJM, 2022)
- The share of weight lost that is muscle, and the finding that no study measured physical functionBatsis et al., effect of incretin-based and nonpharmacologic weight loss on body composition (Annals of Internal Medicine, 2026)
- That facial change on a GLP-1 is a consequence of rapid weight loss rather than a novel drug effectCarboni et al., natural weight loss or Ozempic face (Journal of Drugs in Dermatology, 2024)
- The proposed mechanisms beyond fat volume, and that they are unresolvedRidha et al., decoding the implications of GLP-1 receptor agonists on accelerated facial and skin aging (Aesthetic Surgery Journal, 2024)
- Whether GLP-1 receptor agonists accelerate skin aging, concluding the mechanisms have to be elucidatedPaschou et al., GLP-1RA and the possible skin aging (Endocrine, 2025)
- Where cosmetic facial change sits among the documented dermatologic effects, across 51 studiesPersson et al., a closer look at the dermatological profile of GLP-1 agonists (Diseases, 2025)
- What clinicians use for facial volume loss and skin laxity after GLP-1 weight lossHaykal et al., the role of GLP-1 agonists in esthetic medicine (Journal of Cosmetic Dermatology, 2025)
- Fillers, skin tightening and surgery as the interventions for facial volume and excess skinHumphrey and Lawrence, implications of semaglutide medications for facial plastic surgeons (Facial Plastic Surgery, 2023)
- Telogen effluvium as the pattern of GLP-1-associated sheddingBurke et al., dermatologic implications of GLP-1 receptor agonist medications (Skin Appendage Disorders, 2025)
- An association between GLP-1 receptor agonist use and hair loss in a retrospective cohortBurke et al., GLP-1 receptor agonist medications and hair loss (Journal of the American Academy of Dermatology, 2025)
- Higher telogen effluvium risk with tirzepatide than with other weight-loss medicationsNeubauer et al., increased risk of telogen effluvium with tirzepatide (Journal of the American Academy of Dermatology, 2025)
- That telogen effluvium follows sudden weight loss, remits, and has no targeted treatmentChien Yin et al., telogen effluvium, a review of the science and current obstacles (Journal of Dermatological Science, 2021)
- Surplus skin prevalence after large surgical weight loss and how many patients want contouringKitzinger et al., after massive weight loss, patients' expectations of body contouring surgery (Obesity Surgery, 2012)
- That body contouring surgery improves quality of life after massive weight lossToma et al., does body contouring after bariatric weight loss enhance quality of life (Obesity Surgery, 2018)
- That daily sunscreen use retards measurable skin agingHughes et al., sunscreen and prevention of skin aging, a randomized trial (Annals of Internal Medicine, 2013)
- That topical tretinoin improves photoaged skinWeiss et al., topical tretinoin improves photoaged skin, a double-blind vehicle-controlled study (JAMA, 1988), on PubMed
- That an over-the-counter retinol formulation was not significantly different from tretinoin on photoaging score in one 24-week trial of 20 patientsChien et al., biomarkers of tretinoin precursors and tretinoin efficacy (JAMA Dermatology, 2022)
- The evidence grade behind topical peptides for photoaged skinChan et al., cosmeceuticals in photoaging, a review (Skin Research and Technology, 2024)
- That the published GHK-Cu work is cell-culture and animal work on collagen synthesis and wound repairPickart and Margolina, GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration (BioMed Research International, 2015)
- That peptide penetration through the stratum corneum is unresolvedZdrada-Nowak et al., acetyl hexapeptide-8 in cosmeceuticals, a review of skin permeability and efficacy (International Journal of Molecular Sciences, 2025)
- That resistance exercise mitigates the fall in muscle protein synthesis during energy restrictionHector et al., pronounced energy restriction with elevated protein intake (FASEB Journal, 2017)
- That higher protein and exercise additively improve body composition during weight lossLayman et al., dietary protein and exercise have additive effects on body composition during weight loss (Journal of Nutrition, 2005)
- The legal line between a cosmetic claim and a drug claimFDA, is it a cosmetic, a drug, or both
